COVID-19 and diabetes: What do we know so far?

Gangadaran, Prakash; Padinjarathil, Himabindu; Rajendran, Shri Hari Subhashri; Jogalekar, Manasi P.; Hong, Chae Moon; Aruchamy, Baladhandapani; Rajendran, Uma Maheswari; Sridharan, Gopalan; Krishnan, Anand; Ramani, Prasanna; Kavimani, S

doi:10.1177/15353702221108914

Cited by 9 publications

(12 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5,10 The most significant risks for hospitalized people with diabetes from COVID-19 were seen in studies conducted in the Western Pacific, Africa, and South and Central America. 4,11 Considering additional risks lowered the death rate, although it was still relatively high. In patients with both diabetes and COVID-19, symptoms and disease progression are extreme.…”

Section: Diabetes and Covid-19mentioning

confidence: 99%

“…Some of these complications include hyperglycemia, insulin resistance, diminished pancreatic function, and the development of ages. 11,12 COVID-19 and DM have bidirectional effects on one another, where each condiction can worsen other, creating a vicious circle or interplay. It is reported that up to 50% of individuals who have succumbed to COVID-19 were afflicted with vascular and metabolic disorders, including DM.…”

Section: Diabetes and Covid-19mentioning

confidence: 99%

“…The poor prognosis of COVID‐19 diabetic individuals is due to a combination of factors. Some of these complications include hyperglycemia, insulin resistance, diminished pancreatic function, and the development of ages 11,12 . COVID‐19 and DM have bidirectional effects on one another, where each condiction can worsen other, creating a vicious circle or interplay.…”

Section: Diabetes and Covid‐19mentioning

confidence: 99%

See 2 more Smart Citations

Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused

Hossain,

Al‐Mamun,

Islam

2024

Health Science Reports

View full text Add to dashboard Cite

Background and AimsDiabetes is recognized as a significant factor in both mortality and morbidity worldwide, affecting various demographics regardless of geographic location, age group, or gender. This correspondence aims to express concern and draw the attention of leaders and policymakers worldwide to this critical public health issue.MethodsA thorough literature search was conducted utilizing various databases, including Google Scholar, PubMed, Science Direct, and the International Diabetes Federation (IDF) website, to collect the required data. Keywords were strategically applied to enhance search results, with preference given to English‐language articles containing pertinent information.ResultsAccording to the 2021 report by the IDF, approximately 537 million individuals globally were affected with diabetes, constituting roughly 10.5% of the world's populace. This condition incurred healthcare expenditures totaling $966 billion. Projections indicate a surge in diabetes cases to 783 million by 2045, with associated healthcare costs estimated to surpass $1054 billion. However, almost half of all people with diabetes are unaware of their medical condition, with the highest prevalence of undiagnosed diabetes Mellitus (DM) found in low and middle‐income countries (LMICs) of the regions of Africa, the Western Pacific, and Southeast Asia.ConclusionCollaborating with the World Health Organization (WHO), LMIC governments should improve healthcare accessibility, including more frequent diabetes screenings for individuals aged ≥ 45 years and younger individuals at elevated risk of having a family history.

show abstract

Section: Diabetes and Covid-19mentioning

confidence: 99%

Section: Diabetes and Covid-19mentioning

confidence: 99%

Section: Diabetes and Covid‐19mentioning

confidence: 99%

See 1 more Smart Citation

Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused

Hossain,

Al‐Mamun,

Islam

2024

Health Science Reports

View full text Add to dashboard Cite

show abstract

“…[8,9] Diabetic patients are at higher risk of contracting COVID-19, and their hospitalization rate, severe pneumonia, and mortality rate are higher than non-diabetic patients, as reported in many studies. [10][11][12][13][14][15][16] The pro-inflammatory state, immune dysfunction driven by hyperglycemia, [17,18] and increased microbial virulence in diabetes patients make them susceptible to virus invasion and worsen symptoms after viral infection. In addition to diabetes itself, whether hypoglycemic agents exacerbate the COVID-19 condition of diabetic patients, which is a factor that increases hospitalization, severity, and mortality rates of diabetic and COVID-19 patient?…”

Section: Introductionmentioning

confidence: 99%

GDF-15 (a biomarker for metformin) and the risk of COVID-19: A two-sample Mendelian randomization study

Wang,

Yao,

et al. 2023

Medicine

View full text Add to dashboard Cite

Background: Regarding the impact of metformin on COVID-19, there are currently varying opinions from multiple studies. Growth differentiation factor 15 (GDF-15) is a biomarker of metformin use and dosage, and we used two-sample Mendelian randomization (MR) to assess the causal effect of GDF-15 (metformin) on COVID-19 susceptibility, hospitalization, and severe COVID-19, thereby guiding the selection of glucose-lowering agents for diabetic patients during the COVID-19 pandemic. Methods: Two sets of genetic tools were utilized for MR analysis, derived from publicly available genetic data. The first set was GDF-15 genome-wide association study (GWAS) data from a study with 5440 participants, while the second set was COVID-19 GWAS data from the Host Genetics Initiative (HGI) GWAS meta-analysis. The primary method used to assess causal effects was random effects inverse variance weighted estimation. Complementary methods included weighted median and MR-Egger analyses. Sensitivity analysis was performed using Cochran Q tests, MR-Egger intercept tests, MR-PRESSO, leave-one-out analyses, and funnel plots. Results: GDF-15 increased the risk of severe COVID-19 in patients (OR = 1.10, 95% CI 1.03–1.19; P = .006); there was no causal effect of GDF-15 on hospitalization for COVID-19 (OR = 1.02, 95% CI 0.96–1.07; P = .47) or susceptibility to COVID-19 in the general population (OR = 1.010, 95% CI 0.988–1.034; P = .354). Conclusions: Our study supports the notion that GDF-15 increases the risk of severe COVID-19 in patients. However, there is no causal relationship between GDF-15 and hospitalization or susceptibility to COVID-19.

show abstract

“…[5] Diabetes had been addressed as a main factor that increases risk of complications and mortality for those with COVID-19 infection. [6][7][8] The relationship between diabetes and COVID-19 infection was discussed by Gangadaran et al [9] in their review paper where they indicated that diabetes is linked [10] to the severity of the COVID-19 and its rapid progression. The negative impact of diabetes on the health outcomes of patients with COVID-19 was attributed to hyperglycemic changes and immune responses.…”

Section: Introductionmentioning

confidence: 99%

Role of inflammation in determining the severity of COVID-19 infection in patients with diabetes: A comparative study

Gharaibeh,

Abuhammad,

Haneyah

et al. 2023

Medicine

View full text Add to dashboard Cite

There is a need to consider the geographical origins when studying the association between COVID-19 and the comorbid conditions. To examine the role of inflammation in determining the severity of COVID-19 among hospitalized patients with diabetes and compare these roles with those who does not have diabetes. A cross sectional comparative design was used with a convenience sample of 352 patients. Samples were collected from hospitalized patients with COVID-19 who were divided into 2 groups (diabetes and non-diabetes). Data regarding results of selected inflammatory markers and sociodemographic were collected. The severity of COVID-19 differed significantly between the diabetes and non-diabetes groups (Chi square = 25.58 P < .05). There was significant difference in the mean scores of neutrophil counts, monocyte count, Basophil count, erythrocyte sedimentation rate, partial thromboplastin time, C-creative protein, platelets, white blood cells, and mean cellular hemoglobin center between those with and those without diabetes. The diabetes were shown more increased in the predictors and severity of the COVID-19 disease. However, neutrophil to lymphocyte ratio, neutrophil count, and age were the significant predictors of the severity level of COVID-19 among patients with diabetes. In conclusion, our study addressed the influence of having diabetes among hospitalized patients with moderate and severe COVID-19 infection. The results showed that severity of COVID-19 infection was affected by diabetes where those with diabetes had more tendency to suffer from the severe form of the disease rather that the moderate level.

show abstract

COVID-19 and diabetes: What do we know so far?

Cited by 9 publications

References 48 publications

Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused

Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused

GDF-15 (a biomarker for metformin) and the risk of COVID-19: A two-sample Mendelian randomization study

Role of inflammation in determining the severity of COVID-19 infection in patients with diabetes: A comparative study

Contact Info

Product

Resources

About